Morie Gertz, MD, Hematologist, Chair Emeritus Internal Medicine, at the Mayo Clinic, gives an overview of immunoglobulin light chain-associated (AL) amyloidosis and how the disease is currently managed.
As Dr. Gertz explains, AL amyloidosis is a rare blood disorder associated with the overproduction of amyloid. This leads to the deterioration of vital organs, most notably the heart, kidneys, and liver. The heterogeneity of this disease makes it difficult to diagnose and treat. There is no genetic predisposition for AL amyloidosis nor are there specific environmental factors associated with the disease.
Dr. Gertz also discusses current management strategies. As he explains, all therapies for this disease are directed at the production of amyloid fibrils by targeting the plasma cells that are the source of the amyloid protein with cytotoxic chemotherapy. As a result, the efficacy of treatment is dependent on how early patients are diagnosed and treated.
To learn more about AL amyloidosis and other rare blood disorders, visit checkrare.com/diseases/hematologic-disorders/.
